Darovasertib data are promised for the last week of March.
ApexOnco Front Page
Recent articles
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
The company will acquire ImCheck for €350m.
Redemption of sorts comes for IO Biotech, but there’s no respite for Summit.
But Perspective sinks again.
Response rates with INCB161734 in pancreatic cancer look in line with Revolution.
Amgen and Zai Lab’s FGFR2b antibody shows no benefit at the two-year mark.
The Stellar-303 trial of zanzalintinib hits, but the discussant asks for more data and flags toxicity.
